Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA3 | P07451 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20536196 | 0.91 | CA3 (0.43) | CA2CA3CA5ACA5BCA12 | |
| SCHEMBL629320 | 0.90 | — | — | |
| SCHEMBL3483791 | 0.90 | CA3 (0.50) | CA2CA3CA5ACA5BCA12 | |
| Hydrochloric Acid SCHEMBL4333850 | 0.87 | — | — | |
| SCHEMBL18338812 | 0.87 | CA3 (0.54) | CA2CA3CA5ACA5BCA12 | |
| SCHEMBL23069642 | 0.85 | CA12 (0.50) | CA2CA3CA5ACA5BCA12 | |
| SCHEMBL6558266 | 0.84 | PAOX (0.42) | CA2CA3CA5ACA5BCA12 | |
| SCHEMBL380758 | 0.82 | — | — | |
| Bicarbonate SCHEMBL28175204 | 0.82 | CAMK2A (0.43) | CA2CA3CA5ACA5BCA12 | |
| Bicarbonate SCHEMBL28175203 | 0.82 | CAMK2A (0.43) | CA2CA3CA5ACA5BCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240122854-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2024-04-18 | — | — | US | disclosed |
| EP-3615510-B1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | ACUITAS THERAPEUTICS INC (CA) | 2024-03-27 | — | — | EP | disclosed |
| US-11820728-B2 | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | Acuitas Therapeutics, Inc. (CA) | 2023-11-21 | — | — | US | disclosed |
| US-20220081392-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2022-03-17 | — | — | US | disclosed |
| EP-3615510-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018200943-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | Acuitas Therapeutics, Inc. (CA) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018191719-A1 | LIPID DELIVERY OF THERAPEUTIC AGENTS TO ADIPOSE TISSUE | Acuitas Therapeutics, Inc. (CA) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820728-B2 | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | TTPA, ACAA2, CPT2 | CA2 1390/4885CA3 1206/4885CA5A 936/4885 |
| US-20220081392-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | TTPA, ACAA2, POLRMT | CA2 1860/4885CA3 1574/4885CA5A 955/4885 |
| US-20240122854-A1 | NOVEL CARBONYL LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS | LMNB1, TTPA, ACAA2 | CA2 2014/4885CA3 1514/4885CA5A 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.